In the past week, UNCY stock has gone up by 4.34%, with a monthly gain of 24.74% and a quarterly surge of 4.56%. The volatility ratio for the week is 9.04%, and the volatility levels for the last 30 days are 14.79% for Unicycive Therapeutics Inc The simple moving average for the past 20 days is 5.44% for UNCY’s stock, with a 23.85% simple moving average for the past 200 days.
Is It Worth Investing in Unicycive Therapeutics Inc (NASDAQ: UNCY) Right Now?
Company’s 36-month beta value is 2.00.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for UNCY is 10.48M, and currently, short sellers hold a 0.34% ratio of that floaft. The average trading volume of UNCY on June 24, 2025 was 340.07K shares.
UNCY) stock’s latest price update
Unicycive Therapeutics Inc (NASDAQ: UNCY)’s stock price has increased by 1829833 compared to its previous closing price of 6.34. However, the company has seen a 4.34% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-17 that Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025 Shares Expected to Begin Trading on Split-Adjusted Basis on June 20, 2025
Analysts’ Opinion of UNCY
Many brokerage firms have already submitted their reports for UNCY stocks, with Guggenheim repeating the rating for UNCY by listing it as a “Buy.” The predicted price for UNCY in the upcoming period, according to Guggenheim is $6 based on the research report published on April 21, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see UNCY reach a price target of $9. The rating they have provided for UNCY stocks is “Overweight” according to the report published on April 04th, 2024.
UNCY Trading at 12.42% from the 50-Day Moving Average
After a stumble in the market that brought UNCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.36% of loss for the given period.
Stock Fundamentals for UNCY
The total capital return value is set at -2.74. Equity return is now at value -2355.27, with -52.73 for asset returns.
Based on Unicycive Therapeutics Inc (UNCY), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -56.61. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -858.39.
Currently, EBITDA for the company is -36.23 million with net debt to EBITDA at 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.64.
Conclusion
In a nutshell, Unicycive Therapeutics Inc (UNCY) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
